The global Oncolytic Virus Immunotherapy Market was valued at USD 110.2 Mn in 2022 and is projected to witness strong growth, reaching USD 572.2 Mn by the end of 2031. Expanding at a robust CAGR of 21.1% from 2023 to 2031, the market is being driven by rising advancements in cancer immunotherapy, increasing prevalence of cancer, growing investments in biotechnology research, and the development of innovative virus-based treatments that selectively target and destroy cancer cells while enhancing immune response.

Growth in the prevalence of cancer and a rise in healthcare spending are primary factors augmenting the oncolytic virus immunotherapy market value. Around 40% of men and women are likely to be diagnosed with cancer at some point in their lifetime.

Transform Your Strategy: Explore In-Depth Data – Sample Available! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44931

Under oncolytic virus therapy, viruses are used to infect and destroy cancer cells. An increase in clinical trials in oncolytic virus immunotherapy is also boosting market progress.

Companies operating in the global oncolytic virus immunotherapy market are investing in R&D activities to launch technically advanced products.

The Cold-to-Hot Tumor Conversion: One of the most promising aspects of oncolytic virus immunotherapy is its ability to turn immunologically “cold” tumors (those that lack T-cell infiltration and ignore standard therapies) into “hot” tumors. By expressing immune-modulating genes like GM-CSF or IL-12 directly within the tumor microenvironment, OVs create the “danger signals” needed to recruit a powerful, localized immune response.

Global Oncolytic Virus Immunotherapy Market Trends

1. Combination Therapy Approaches Spark Commercial Acceleration

The growing adoption of combination therapies is a primary growth-shaping trend in this landscape. Biopharmaceutical companies are increasingly pairing oncolytic viruses with immune checkpoint inhibitors (such as anti-PD-1/PD-L1 therapies) or chemotherapy to overcome tumor resistance.

Clinical data continues to support this paradigm shift. For instance, in clinical evaluations involving patients with unresectable Stage III–IV melanoma, combining the oncolytic virus Talimogene laherparepvec (T-VEC) with a checkpoint inhibitor produced an objective response rate (ORR) of 35.7%, compared to just 16.0% for the inhibitor alone. This synergy dramatically expands the therapeutic potential of viral platforms, drawing substantial venture capital and big pharma investment.

2. Advanced Viral Engineering Overcomes Historical Restraints

Historically, variability in patient clinical response acted as a restraint for broad commercial uptake. However, rapid advancements in genetic engineering and artificial intelligence (AI) integration are unlocking new growth opportunities. AI and advanced genomic edits allow developers to engineer next-generation viruses with enhanced tumor-selectivity and customizable payloads.

By tailoring viral vectors to target explicit intracellular proteins—such as non-small-cell lung cancer markers or specific glioblastoma pathways—stakeholders are creating highly differentiated product portfolios that minimize off-target effects and safely pass through cell membranes.

Regional Insights

North America Holds the Top Position

North America dominated the global revenue share, contributing roughly 43.1% of the market. The region’s top position is sustained by an established commercial foundation (anchored by FDA-approved treatments like Amgen’s Imlygic), robust clinical research networks, and major capital sponsorships from domestic drug developers. Furthermore, the high incidence of solid tumors and a highly supportive regulatory framework—including accelerated approval pathways for advanced biologics—position North America to maintain its dominance throughout the forecast period.

Asia-Pacific Anticipated as the Fastest-Growing Hub

The Asia-Pacific region is estimated to record the most rapid growth during the forecast period. Driven by heavy investments in medical infrastructure, lower clinical trial operational costs, and expanding public-private biotech initiatives, countries like China and Japan are scaling their immuno-oncology pipelines quickly. China’s market alone is showing remarkable momentum, attracting global firms eager to establish technology transfers and multi-center clinical trials in the region.

Customize this report according to your needs@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=44931

Leading Players and Strategic Moves

Prominent players operating in the global biotech and oncolytic virus immunotherapy market include:

• Amgen Inc.
• CG Oncology
• Daiichi Sankyo Co., Ltd.
• Genelux Corporation
• Merck & Co., Inc.
• Replimune Group Inc.
• Imugene Limited
• SillaJen, Inc.
• Oncolytics Biotech Inc.

Key Industrial Developments:

• Pipeline Acceleration: As clinical evidence accumulates, major oncology market leaders are entering into strategic licensing agreements to secure cutting-edge viral replication enhancement technologies, pushing over 400 registered clinical trials globally into Phase I and Phase II stages.
• Manufacturing Investment: Due to the complex biosafety protocols and precise cold-chain logistics required to manufacture biological viral vectors, leading Contract Development and Manufacturing Organizations (CDMOs) are rapidly expanding specialized fermentation and viral fill-finish infrastructure to support global supply demands.

Oncolytic Virus Immunotherapy Market Segmentation

By Virus Type

• Herpes Simplex Virus (HSV): Holds a dominant market share owing to its large genome capacity for carrying therapeutic payloads and its strong track record in clinical safety.
• Adenoviruses: Rapidly expanding segment due to high transduction efficiency and clear structural advantages in genetic engineering.
• Vaccinia Virus / Reovirus / Others: Emerging replication platforms utilized for specialized solid tumor targets.

By Application

• Melanoma: The most lucrative historical application, backed by established clinical protocols.
• Solid Tumors: Leading the pipeline expansion across breast cancer, lung cancer, ovarian cancer, and glioblastoma indications.

By End-User

• Hospitals & Specialty Clinics: Accounting for the largest commercial demand share due to the specialized infrastructure required for intratumoral and intravenous administration.
• Cancer Research Institutes: The fastest-growing segment for pipeline optimization and early-stage academic development.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=44931&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com